Questions about Myasthenia Gravis
Which specific antibodies must be present for Epysqli approval in myasthenia gravis?
Epysqli (eculizumab-sbja) is FDA-approved for generalized myasthenia gravis only in adult patients who test positive for anti-acetylcholine receptor (AChR) antibodies.
Full answer →Can thymoma be associated with myasthenia gravis and stiff person syndrome?
Yes, thymoma can be associated with both myasthenia gravis and stiff person syndrome, though this combination is very rare.
Full answer →Do complement inhibitors improve outcomes for myasthenia gravis patients?
Yes, complement inhibitors (eculizumab, ravulizumab, zilucoplan) significantly improve symptoms and daily functioning in AChR antibody-positive generalized myasthenia gravis, based on multiple trials and real-world studies.
Full answer →Is there a link between myasthenia gravis and the risk of autoimmune encephalitis?
Yes, people with myasthenia gravis have an increased risk of developing autoimmune encephalitis, likely due to shared autoimmune mechanisms and overlapping antibody targets.
Full answer →Can a ketogenic diet improve quality of life for myasthenia gravis adults?
Early research suggests a ketogenic diet may improve symptoms and quality of life in myasthenia gravis, but evidence is limited to one small pilot study.
Full answer →Does efgartigimod help improve symptoms for myasthenia gravis patients?
Yes, efgartigimod helps improve symptoms in myasthenia gravis patients, with most studies showing clinically meaningful improvements in daily living scores and muscle strength.
Full answer →All Myasthenia Gravis Articles
- Rare overlap of myasthenia gravis and Kennedy's disease identified in case report
- Meta-analysis of efgartigimod for myasthenia gravis reports efficacy and safety outcomes
- FDA Approves Epysqli (eculizumab-sbja) for PNH, aHUS, and gMG
- Case report and literature review of thymoma associated with stiff person syndrome and myasthenia gravis
- Pilot study explores ketogenic diet effects on symptoms in adults with generalized myasthenia gravis
- Low-dose IVIG shows similar efficacy to standard-dose IVIG in adults with AChR-positive generalized myasthenia gravis
- Efgartigimod improved MG-ADL and QMG scores in 81 Chinese patients with generalized myasthenia gravis
- Narrative review links myasthenia gravis and autoimmune encephalitis risk
- Efgartigimod shows homogeneous efficacy across sexes in AChR-Ab+ generalized myasthenia gravis
- Pyridostigmine improves symptoms and reduces costs in adults with AChR MG in a crossover trial
- Complement inhibitors and FcRn blockers improve outcomes in AChR-Ab+ generalized myasthenia gravis
- CD19/BCMA CAR-T cells show early signal in six patients with refractory generalized myasthenia gravis
- Autoantibodies neutralizing type I interferons linked to severe COVID-19 pneumonia in myasthenia gravis patients